| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1004527104 |
| P356 | DOI | 10.1007/S11906-014-0511-3 |
| P698 | PubMed publication ID | 25447989 |
| P2093 | author name string | George S Chrysant | |
| Steven G Chrysant | |||
| P2860 | cites work | 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration | Q22306346 |
| Standards of medical care in diabetes--2012 | Q24632533 | ||
| Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
| Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease | Q33158176 | ||
| A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure | Q34106793 | ||
| Proinflammatory actions of angiotensins. | Q34244757 | ||
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial | Q34246891 | ||
| Vascular remodeling: the role of angiotensin-converting enzyme inhibitors | Q34458849 | ||
| ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the | Q34640762 | ||
| Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension | Q36088984 | ||
| The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease | Q36335340 | ||
| The pleiotropic effects of angiotensin receptor blockers | Q36440956 | ||
| Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials | Q36456291 | ||
| Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials | Q36564282 | ||
| Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials | Q36567554 | ||
| Bayesian meta-analysis of tissue angiotensin-converting enzyme inhibitors for reduction of adverse cardiovascular events in patients with diabetes mellitus and preserved left ventricular function | Q37104532 | ||
| Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysi | Q37125268 | ||
| Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study | Q37368689 | ||
| Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). | Q37369476 | ||
| Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system | Q37387558 | ||
| The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade | Q37692452 | ||
| Current status of dual Renin Angiotensin aldosterone system blockade for the treatment of cardiovascular diseases | Q37704702 | ||
| The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan | Q37751926 | ||
| Renin Angiotensin Aldosterone System Blockade: Little to No Rationale for ACE Inhibitor and ARB Combinations | Q37824165 | ||
| Combination inhibition of the renin-angiotensin system: is more better? | Q37883908 | ||
| Combinations of renin-angiotensin-aldosterone system antagonists: true advantages? | Q37979298 | ||
| Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial | Q38454911 | ||
| Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension | Q38497893 | ||
| Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both | Q39669015 | ||
| Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease | Q39895582 | ||
| Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure | Q43266277 | ||
| Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators | Q43644352 | ||
| Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial | Q44280775 | ||
| Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy | Q44390528 | ||
| Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial | Q44526964 | ||
| Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting | Q44581514 | ||
| Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure | Q44824452 | ||
| Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial | Q45027934 | ||
| Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials | Q45057353 | ||
| Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption | Q45173412 | ||
| Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. | Q45242324 | ||
| Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. | Q46016219 | ||
| Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy | Q46157336 | ||
| Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure | Q46291373 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study | Q46579672 | ||
| Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats | Q47298474 | ||
| Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators | Q48118604 | ||
| Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized | Q50653081 | ||
| Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. | Q55042793 | ||
| Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction | Q57243489 | ||
| Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction | Q57396225 | ||
| Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system | Q57583262 | ||
| Pathophysiology of Progressive Nephropathies | Q57703963 | ||
| Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study | Q61455603 | ||
| Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial | Q61455820 | ||
| Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension | Q70838730 | ||
| Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan | Q79470523 | ||
| Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis | Q79969450 | ||
| Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial | Q80688403 | ||
| Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials | Q81310848 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 511 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Current Hypertension Reports | Q15746362 |
| P1476 | title | Dual renin-angiotensin-aldosterone blockade: promises and pitfalls | |
| P478 | volume | 17 |
| Q37347190 | New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option? | cites work | P2860 |
Search more.